A detailed history of Peregrine Capital Management LLC transactions in Ultragenyx Pharmaceutical Inc. stock. As of the latest transaction made, Peregrine Capital Management LLC holds 134,204 shares of RARE stock, worth $6.09 Million. This represents 0.23% of its overall portfolio holdings.

Number of Shares
134,204
Previous 148,813 9.82%
Holding current value
$6.09 Million
Previous $6.12 Million 21.89%
% of portfolio
0.23%
Previous 0.18%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 24, 2024

SELL
$40.21 - $59.36 $587,427 - $867,190
-14,609 Reduced 9.82%
134,204 $7.46 Million
Q2 2024

Jul 29, 2024

BUY
$37.42 - $51.61 $1.1 Million - $1.52 Million
29,474 Added 24.7%
148,813 $6.12 Million
Q1 2024

Apr 26, 2024

BUY
$43.02 - $53.69 $1,677 - $2,093
39 Added 0.03%
119,339 $5.57 Million
Q4 2023

Jan 26, 2024

SELL
$31.73 - $49.19 $652,686 - $1.01 Million
-20,570 Reduced 14.71%
119,300 $5.7 Million
Q3 2023

Oct 19, 2023

SELL
$34.92 - $46.66 $306,388 - $409,394
-8,774 Reduced 5.9%
139,870 $4.99 Million
Q2 2023

Jul 26, 2023

SELL
$37.35 - $52.15 $1,606 - $2,242
-43 Reduced 0.03%
148,644 $6.86 Million
Q1 2023

Apr 26, 2023

BUY
$36.99 - $48.71 $162,053 - $213,398
4,381 Added 3.04%
148,687 $5.96 Million
Q4 2022

Jan 10, 2023

BUY
$33.72 - $46.33 $855,712 - $1.18 Million
25,377 Added 21.34%
144,306 $6.69 Million
Q3 2022

Oct 26, 2022

SELL
$39.96 - $66.14 $262,816 - $435,002
-6,577 Reduced 5.24%
118,929 $4.93 Million
Q2 2022

Jul 20, 2022

SELL
$45.8 - $85.4 $4,488 - $8,369
-98 Reduced 0.08%
125,506 $7.49 Million
Q1 2022

Apr 27, 2022

BUY
$62.2 - $84.4 $7.81 Million - $10.6 Million
125,604 New
125,604 $9.12 Million

Others Institutions Holding RARE

About Ultragenyx Pharmaceutical Inc.


  • Ticker RARE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 70,036,896
  • Market Cap $3.18B
  • Description
  • Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...
More about RARE
Track This Portfolio

Track Peregrine Capital Management LLC Portfolio

Follow Peregrine Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Peregrine Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Peregrine Capital Management LLC with notifications on news.